Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:OGN NASDAQ:PHAR NASDAQ:TLX NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOGNOrganon & Co.$13.46+0.0%$11.47$5.69▼$13.49$3.53B1.552.77 million shs1.82 million shsPHARPharming Group$12.81-0.5%$14.67$9.54▼$21.34$909.65M-0.0411,006 shs6,849 shsTLXTelix Pharmaceuticals$9.56+1.2%$10.07$6.28▼$17.30$3.21B-0.11154,081 shs386,781 shsVKTXViking Therapeutics$28.75+0.5%$31.90$22.96▼$43.15$3.32B0.691.96 million shs1.18 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOGNOrganon & Co.+0.75%+0.60%+1.20%+112.04%+33.35%PHARPharming Group+4.89%+3.29%-1.60%-11.23%+11.37%TLXTelix Pharmaceuticals+0.11%-0.94%-9.05%+20.38%-44.54%VKTXViking Therapeutics+3.10%-3.93%-8.65%-19.70%-1.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOGNOrganon & Co.$13.46+0.0%$11.47$5.69▼$13.49$3.53B1.552.77 million shs1.82 million shsPHARPharming Group$12.81-0.5%$14.67$9.54▼$21.34$909.65M-0.0411,006 shs6,849 shsTLXTelix Pharmaceuticals$9.56+1.2%$10.07$6.28▼$17.30$3.21B-0.11154,081 shs386,781 shsVKTXViking Therapeutics$28.75+0.5%$31.90$22.96▼$43.15$3.32B0.691.96 million shs1.18 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOGNOrganon & Co.+0.75%+0.60%+1.20%+112.04%+33.35%PHARPharming Group+4.89%+3.29%-1.60%-11.23%+11.37%TLXTelix Pharmaceuticals+0.11%-0.94%-9.05%+20.38%-44.54%VKTXViking Therapeutics+3.10%-3.93%-8.65%-19.70%-1.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOGNOrganon & Co. 1.71Reduce$11.40-15.27% DownsidePHARPharming Group 2.40Hold$38.33199.25% UpsideTLXTelix Pharmaceuticals 2.78Moderate Buy$21.13120.97% UpsideVKTXViking Therapeutics 2.79Moderate Buy$93.60225.57% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, OGN, VKTX, and TLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026VKTXViking Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$89.005/27/2026VKTXViking Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$83.005/15/2026OGNOrganon & Co. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/1/2026VKTXViking Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.004/30/2026VKTXViking Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.004/30/2026VKTXViking Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$105.00 ➝ $100.004/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2026OGNOrganon & Co. Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$5.00 ➝ $14.004/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOGNOrganon & Co.$6.22B0.57$5.80 per share2.32$2.89 per share4.66PHARPharming Group$376.13M2.41$0.20 per share64.22$3.95 per share3.24TLXTelix Pharmaceuticals$803.79M4.04$0.04 per share224.13$1.23 per share7.77VKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOGNOrganon & Co.$187M$0.934.283.911.243.99%99.95%6.22%8/4/2026 (Estimated)PHARPharming Group$2.85M$0.1680.0719.71N/A3.30%4.64%2.55%7/30/2026 (Estimated)TLXTelix Pharmaceuticals-$7.12MN/AN/A86.91N/AN/AN/AN/A8/20/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest PHAR, OGN, VKTX, and TLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/A3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthOGNOrganon & Co.$0.080.59%N/A8.60%N/APHARPharming GroupN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ALatest PHAR, OGN, VKTX, and TLX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOGNOrganon & Co.9.471.971.42PHARPharming Group0.352.632.06TLXTelix Pharmaceuticals1.081.431.27VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOGNOrganon & Co.77.43%PHARPharming Group0.03%TLXTelix PharmaceuticalsN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipOGNOrganon & Co.1.62%PHARPharming Group2.07%TLXTelix PharmaceuticalsN/AVKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionablePHARPharming Group28070.62 million69.16 millionNot OptionableTLXTelix Pharmaceuticals1,184339.38 millionN/AN/AVKTXViking Therapeutics20116.11 million109.95 millionOptionablePHAR, OGN, VKTX, and TLX HeadlinesRecent News About These CompaniesViking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And ValuationJune 12 at 9:03 AM | finance.yahoo.comIs Viking Therapeutics Stock Going to $100?June 12 at 1:15 AM | fool.comViking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical OfficerJune 11 at 9:40 AM | finance.yahoo.comViking Therapeutics Announces Appointment of Hubert C. Chen, M.D.June 11 at 7:05 AM | prnewswire.comViking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowJune 10 at 12:02 AM | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowJune 10 at 6:50 PM | zacks.comWhy 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%June 10 at 2:00 PM | fool.comInside the GLP-1 Boom: ETF Picks for the Obesity Drug MarketJune 10 at 1:01 PM | zacks.comViking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderJune 4, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderJune 4, 2026 | zacks.comViking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 4, 2026 | seekingalpha.comShould Viking’s VK2735 Obesity Program Advancements Require Action From Viking Therapeutics (VKTX) Investors?June 3, 2026 | finance.yahoo.com1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn'tJune 3, 2026 | fool.comVKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% UpsideJune 2, 2026 | stocktwits.comSLake Street initiates coverage of Viking Therapeutics (VKTX) with buy recommendationMay 29, 2026 | msn.comWhy Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?May 29, 2026 | finance.yahoo.comWhy Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?May 29, 2026 | zacks.comViking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderMay 28, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderMay 28, 2026 | zacks.comViking Therapeutics (VKTX) Initiated with a Buy at Truist FinancialMay 28, 2026 | theglobeandmail.comViking Therapeutics Faces Timeline Risk—But Upside Could Be Huge...May 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026Eli Lilly Wins Back CVS Health, Reverting Novo's AdvantageBy Leo Miller | June 2, 2026PHAR, OGN, VKTX, and TLX Company DescriptionsOrganon & Co. NYSE:OGN$13.46 +0.01 (+0.04%) Closing price 03:59 PM EasternExtended Trading$13.44 -0.02 (-0.11%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Pharming Group NASDAQ:PHAR$12.81 -0.07 (-0.54%) Closing price 04:00 PM EasternExtended Trading$13.00 +0.19 (+1.48%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Telix Pharmaceuticals NASDAQ:TLX$9.56 +0.11 (+1.16%) Closing price 04:00 PM EasternExtended Trading$9.56 -0.01 (-0.05%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.Viking Therapeutics NASDAQ:VKTX$28.75 +0.14 (+0.49%) Closing price 04:00 PM EasternExtended Trading$28.88 +0.13 (+0.44%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
